Please login to the form below

Not currently logged in
Email:
Password:

Ilumya

This page shows the latest Ilumya news and features for those working in and with pharma, biotech and healthcare.

BMS psoriasis drug hits the mark in phase II

BMS psoriasis drug hits the mark in phase II

including Johnson &Johnson’s Stelara (ustekinumab) and follow-up Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie’s recently-filed risankizumab.

Latest news

  • Sun Pharma passes milestone with novel psoriasis drug approval Sun Pharma passes milestone with novel psoriasis drug approval

    Sun Pharma passes milestone with novel psoriasis drug approval. Ilumya will treat adults with a moderate-to-severe form of the skin condition. ... We are committed to working with all relevant stakeholders to make Ilumya available to appropriate people

  • Archive listing

    Ilumya will treat adults with a moderate-to-severe form of the skin condition. .

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics